LC
KRTX

Lindbrook Capital’s Karuna Therapeutics, Inc. Common Stock KRTX Stock Holding History

Lindbrook Capital’s Portfolio KRTX Stock Details KRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-238
Closed -$75.3K – 2775
2023
Q4 		$75.3K Buy
238
+122
+105% +$23.7K 0.01% 608
2023
Q3 		$19.6K Buy
116
+26
+29% +$4.89K ﹤0.01% 1069
2023
Q2 		$19.5K Sell
90
-21
-19% -$4.5K ﹤0.01% 1103
2023
Q1 		$20.2K Sell
111
-29
-21% -$5.55K ﹤0.01% 1062
2022
Q4 		$27.5K Sell
140
-78
-36% -$16.7K ﹤0.01% 920
2022
Q3 		$49K Buy
218
+41
+23% +$8.3K 0.01% 651
2022
Q2 		$22K Sell
177
-65
-27% -$7.47K ﹤0.01% 942
2022
Q1 		$31K Sell
242
-338
-58% -$38.1K ﹤0.01% 857
2021
Q4 		$76K Buy
+580
New +$75K 0.01% 582

Other funds holding KRTX

IA
IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return
S
Sachetta Lynnfield, Massachusetts $206M AUM 26.19% 1-Year Est. Return

Lindbrook Capital's KRTX Position: Q1 2024 in Review

Lindbrook Capital sold out of Karuna Therapeutics, Inc. Common Stock (KRTX) in Q1 2024, closing a stake of 238 shares — an estimated $75.3K sold.

Lindbrook Capital first reported a position in KRTX in Q4 2021 and held it in 9 quarters. The position peaked at $76K in Q4 2021. 2 funds tracked by Wall St. Rank hold KRTX as of Q1 2024.

  • Lindbrook Capital reported no remaining Karuna Therapeutics, Inc. Common Stock position as of Q1 2024 after selling out during the quarter.
  • Lindbrook Capital sold 238 Karuna Therapeutics, Inc. Common Stock shares in Q1 2024, an estimated $75.3K.
  • Lindbrook Capital first reported a position in Karuna Therapeutics, Inc. Common Stock in Q4 2021 and held it in 9 quarters.
  • Lindbrook Capital's Karuna Therapeutics, Inc. Common Stock position peaked at $76K in Q4 2021.
  • 2 funds tracked by Wall St. Rank held Karuna Therapeutics, Inc. Common Stock as of Q1 2024.

Based on Lindbrook Capital's 13F filing for Q1 2024, filed 25 Apr 2024.